AMGN Maintains Buy Rating by UBS -- Price Target Raised to $420
AMGN Maintains Buy Rating by UBS -- Price Target Raised to $420 GuruFocus
Covered in this story
What has happened since
- Amgen is up 16.9% since this was published, 78 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
UBS’s $420 target on $AMGN is on the record and being tracked to Jul 2027 (12-month default), scored on the close that day.
UBS’s track record →Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.